Onyia Jude 4

What Happened

• Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), exercised 11,000 options and immediately sold 11,000 shares on June 1, 2026.
• Exercise: 11,000 shares exercised at a strike of $84.74 per share (total exercise cost ≈ $932,140).
• Sale: 11,000 shares sold in the open market at a weighted average price of $160.25 per share (total proceeds ≈ $1,762,710).
• This sequence (exercise then same-day sale) is a routine liquidity event rather than an explicit directional bet on the stock.

Key Details

• Transaction date: June 1, 2026 (Form filed June 2, 2026 — appears timely).
• Codes: M = option exercise/conversion; S = sale.
• Sale execution: Broker sold shares under a Rule 10b5-1 trading plan adopted Feb 25, 2026 (Footnote F1). The plan could not be amended after adoption per issuer policy.
• Sale price range: shares sold at prices between $160.00 and $160.66 (weighted avg $160.25) (Footnote F2).
• Vesting info: the option vests 1/4 on Nov 29, 2022 then 1/48th monthly thereafter (Footnote F3).
• Shares owned after the transaction: not disclosed in the provided filing.

Context

• This was an exercise of vested options followed by an immediate market sale — effectively converting option value to cash. Because the sale was carried out under a pre-established 10b5-1 plan, it was a pre-planned disposition executed by a broker rather than an ad-hoc open-market sale.